ACHL
Achilles Therapeutics plc [ACHL] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ACHL Stock Summary
Top 10 Correlated ETFs
ACHL
Top 10 Correlated Stocks
ACHL
In the News
ACHL Financial details
Company Rating
Neutral
Market Cap
34.92M
Income
-69.83M
Revenue
0
Book val./share
3.54
Cash/share
3.27
Dividend
-
Dividend %
-
Employees
204
Optionable
No
Shortable
Yes
Earnings
08 May 2024
P/E
-0.5
Forward P/E
-
PEG
1.3
P/S
-
P/B
0.25
P/C
0.24
P/FCF
-14.72
Quick Ratio
7.71
Current Ratio
8.55
Debt / Equity
0.03
LT Debt / Equity
0.01
-
-
EPS (TTM)
-1.75
EPS next Y
-
EPS next Q
-
EPS this Y
-3.85%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
11.9%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
43.86%
Inst Trans
0.88%
ROA
-43%
ROE
-42%
ROC
-0.5%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.74-1.76
52W High
-
52W Low
-
RSI
31
Rel Volume
0.19
Avg Volume
800.07K
Volume
154.11K
Perf Week
-7.76%
Perf Month
-36.26%
Perf Quarter
-11.88%
Perf Half Y
-9.89%
-
-
-
-
Beta
1.087
-
-
Volatility
0.02%, 0.2%
Prev Close
-2%
Price
0.784
Change
-4.9%
ACHL Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -8.52 | -0.82 | -2.13 | -1.82 | -1.75 | |
| Operating cash flow per share | -8.61 | -0.62 | -2.07 | -1.52 | -1.22 | |
| Free cash flow per share | -9.19 | -0.91 | -2.34 | -1.71 | -1.24 | |
| Cash per share | 59.44 | 4.38 | 9.29 | 4.43 | 3.29 | |
| Book value per share | 61.72 | 4.66 | 10.1 | 5.03 | 3.56 | |
| Tangible book value per share | 61.72 | 4.66 | 10.1 | 5.03 | 3.56 | |
| Share holders equity per share | 61.72 | 4.66 | 10.1 | 5.03 | 3.56 | |
| Interest debt per share | 0.3 | 0.39 | 0.43 | 0.03 | 0.12 | |
| Market cap | 27.17M | 672.29M | 143.56M | 35.23M | 35.54M | |
| Enterprise value | -69.93M | 510.42M | -110.5M | -129.54M | -91.39M | |
| P/E ratio | -1.94 | -20.25 | -2.35 | -0.49 | -0.51 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -1.92 | -26.62 | -2.42 | -0.59 | -0.73 | |
| PFCF ratio | -1.8 | -18.12 | -2.15 | -0.53 | -0.71 | |
| P/B Ratio | 0.27 | 3.55 | 0.5 | 0.18 | 0.25 | |
| PTB ratio | 0.27 | 3.55 | 0.5 | 0.18 | 0.25 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | 5.19 | -15.49 | 1.81 | 1.73 | 1.14 | |
| EV to operating cash flow | 4.95 | -20.21 | 1.86 | 2.18 | 1.88 | |
| EV to free cash flow | 4.64 | -13.76 | 1.65 | 1.93 | 1.84 | |
| Earnings yield | -0.51 | -0.05 | -0.43 | -2.02 | -1.97 | |
| Free cash flow yield | -0.56 | -0.06 | -0.47 | -1.9 | -1.4 | |
| Debt to equity | 0 | 0.08 | 0.04 | 0.04 | 0.03 | |
| Debt to assets | 0 | 0.07 | 0.04 | 0.04 | 0.03 | |
| Net debt to EBITDA | 7.21 | 4.91 | 4.17 | 2.21 | 1.58 | |
| Current ratio | 26.72 | 11.3 | 14.9 | 10.93 | 8.57 | |
| Interest coverage | 0 | 0 | 0 | 10.71 | 0 | |
| Income quality | 1.01 | 0.76 | 0.97 | 0.84 | 0.7 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.07 | 0.47 | 0.13 | 0.13 | 0.02 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -3.12 | -15.35 | -2.32 | -2.04 | -0.23 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 108.78 | 9.26 | 22.02 | 14.35 | 11.84 | |
| ROIC | -0.13 | -0.15 | -0.2 | -0.37 | -0.51 | |
| Return on tangible assets | -0.13 | -0.15 | -0.19 | -0.32 | -0.43 | |
| Graham Net | 59.29 | 3.81 | 8.71 | 4.2 | 3.01 | |
| Working capital | 99.2M | 171.17M | 265.64M | 178.59M | 128.64M | |
| Tangible asset value | 101.35M | 189.37M | 289.56M | 197.08M | 142.37M | |
| Net current asset value | 99.2M | 158.25M | 257.17M | 173.27M | 126.55M | |
| Invested capital | 0 | 0.08 | 0.04 | 0.04 | 0.03 | |
| Average receivables | 0 | 5.91M | 9.26M | 13.59M | 13.18M | |
| Average payables | 0 | 3.61M | 5.02M | 4.45M | 5.41M | |
| Average inventory | 0 | 1.13M | 3.45M | 4.88M | 2.31M | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 1.09K | 2.96K | 413.23 | 513.39 | 434.26 | |
| Days of inventory on hand | 606.63 | 824.76 | 569.88 | 457.67 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0.34 | 0.12 | 0.88 | 0.71 | 0.84 | |
| Inventory turnover | 0.6 | 0.44 | 0.64 | 0.8 | 4.73M | |
| ROE | -0.14 | -0.18 | -0.21 | -0.36 | -0.49 | |
| Capex per share | -0.57 | -0.29 | -0.27 | -0.19 | -0.03 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.61 | -0.44 | -0.42 | -0.42 | -0.47 | |
| Operating cash flow per share | -0.5 | 0 | 0 | 0.03 | -0.35 | |
| Free cash flow per share | -0.55 | 0 | 0 | 0.03 | -0.36 | |
| Cash per share | 4.39 | 3.99 | 3.6 | 3.5 | 3.27 | |
| Book value per share | 4.99 | 4.66 | 4.36 | 3.83 | 3.54 | |
| Tangible book value per share | 4.99 | 4.66 | 4.36 | 3.83 | 3.54 | |
| Share holders equity per share | 4.99 | 4.66 | 4.36 | 3.83 | 3.54 | |
| Interest debt per share | 0.25 | 0.16 | 0.22 | 0.18 | 0.11 | |
| Market cap | 35.57M | 38.04M | 37.71M | 36.46M | 35.73M | |
| Enterprise value | -129.19M | -112.82M | -97.37M | -96.33M | -91.2M | |
| P/E ratio | -0.37 | -0.54 | -0.56 | -0.55 | -0.48 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -1.8 | -2.13K | -2.17K | 33.95 | -2.51 | |
| PFCF ratio | -1.63 | -2.08K | -2.1K | 36.01 | -2.5 | |
| P/B Ratio | 0.18 | 0.21 | 0.22 | 0.24 | 0.25 | |
| PTB ratio | 0.18 | 0.21 | 0.22 | 0.24 | 0.25 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | 5.66 | 6.08 | 5.38 | 5.04 | 4.92 | |
| EV to operating cash flow | 6.55 | 6.32K | 5.59K | -89.7 | 6.41 | |
| EV to free cash flow | 5.93 | 6.16K | 5.43K | -95.14 | 6.39 | |
| Earnings yield | -0.68 | -0.46 | -0.45 | -0.46 | -0.53 | |
| Free cash flow yield | -0.61 | 0 | 0 | 0.03 | -0.4 | |
| Debt to equity | 0.04 | 0.04 | 0.05 | 0.05 | 0.03 | |
| Debt to assets | 0.04 | 0.04 | 0.04 | 0.04 | 0.03 | |
| Net debt to EBITDA | 7.22 | 8.13 | 7.47 | 6.95 | 6.85 | |
| Current ratio | 10.93 | 10.32 | 9.16 | 8.55 | 8.57 | |
| Interest coverage | -19.33 | 17.01 | 0 | 0 | 0 | |
| Income quality | 0.81 | 1.02 | 1.03 | -0.06 | 0.76 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.1 | 0.03 | 0.03 | -0.06 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -2.47 | -0.41 | -0.43 | -0.05 | -0.04 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 8.26 | 6.8 | 6.43 | 5.99 | 6.11 | |
| ROIC | -0.11 | -0.09 | -0.09 | -0.11 | -0.14 | |
| Return on tangible assets | -0.11 | -0.08 | -0.09 | -0.1 | -0.12 | |
| Graham Net | 4.16 | 3.42 | 3.14 | 3.01 | 2.99 | |
| Working capital | 178.59M | 167.32M | 156.09M | 137.31M | 128.64M | |
| Tangible asset value | 197.08M | 185.2M | 173.88M | 153.52M | 142.37M | |
| Net current asset value | 173.27M | 162.8M | 151.15M | 133.64M | 126.55M | |
| Invested capital | 0.04 | 0.04 | 0.05 | 0.05 | 0.03 | |
| Average receivables | 13.36M | 8M | 11.52M | 16.31M | 9.97M | |
| Average payables | 6.35M | 6.42M | 7.27M | 6.12M | 5.49M | |
| Average inventory | -3.04M | 2.31M | -11.52M | -16.31M | -4.8M | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 557.59 | 0 | 475.2 | 402.4 | 437.49 | |
| Days of inventory on hand | 497.07 | 0 | -1.59K | -721.65 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0.16 | 0 | 0.19 | 0.22 | 0.21 | |
| Inventory turnover | 0.18 | 0 | -0.06 | -0.12 | 1.16M | |
| ROE | -0.12 | -0.09 | -0.1 | -0.11 | -0.13 | |
| Capex per share | -0.05 | 0 | 0 | 0 | 0 |
ACHL Frequently Asked Questions
What is Achilles Therapeutics plc stock symbol ?
Achilles Therapeutics plc is a GB stock and trading under the symbol ACHL
What is Achilles Therapeutics plc stock quote today ?
Achilles Therapeutics plc stock price is $0.784 today.
Is Achilles Therapeutics plc stock public?
Yes, Achilles Therapeutics plc is a publicly traded company.
Company Profile
- Volume Average 800.07K
- Market Capitalization 34.92M
- Employee 204
- CEO Dr. Iraj Ali Ph.D.
- Headquarters London,GB
- IPO Date 2021-03-31
-
Website
https://www.achillestx.com 
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.
